key distinction between GLP and GCP lies in their scope and purpose. GLP focuses on the integrity of non-clinical safety studies (e.g., toxicology), ensuring that lab operations and results are traceable, auditable, and reproducible. GCP, on the other hand, centers around protecting human subjects and ensuring that clinical data is credible, with a focus on consent, ethics, and protocol compliance.

Aspect	GLP (21 CFR Part 58)	GCP (ICH E6 R2)
Scope	Non-clinical safety studies	Clinical trials with human subjects
Regulatory Goal	Data integrity and repeatability of laboratory results	Protection of human subjects and reliability of clinical data
Applicable Phases	Preclinical, animal studies	Phase I–IV clinical trials
Primary Controls	Facilities, equipment, SOPs, raw data documentation	Subject consent, protocol adherence, investigator training

When Bioanalysis Falls Under Both Frameworks

Many organizations encounter challenges when operating within studies that require bioanalytical testing to meet both GLP and GCP expectations. This is particularly true in first-in-human studies (Phase I), where the same lab might process toxicokinetic and pharmacokinetic samples. In these cases, both data integrity and patient protection become focal points.

For example, in a recent MHRA inspection of a large oncology trial, the sponsor’s bioanalytical lab failed to include informed consent identifiers in sample tracking logs, even though the data was ultimately used for safety evaluation. The lack of alignment with GCP led to a critical observation and a follow-up inspection.

Key Areas of Audit Focus for GLP and GCP

• Sample chain of custody documentation linking subject data to lab results
• Method validation under GLP, but performed within the framework of GCP protocols
• Handling of protocol deviations or out-of-specification results
• Training records demonstrating dual competency in GLP and GCP processes
• Retention and archiving procedures that support both frameworks

Common Audit Findings from Global Inspections

Based on audit reports from FDA, EMA, and ANVISA inspections, several themes emerge when reviewing hybrid GLP/GCP environments:

• Missing cross-references between preclinical and clinical SOPs
• Use of GLP-only validation templates in GCP-governed studies
• Inadequate CAPA for bioanalytical deviations that impact subject data
• Discrepancies in freezer logs between preclinical and clinical sample handling
• Failure to document subject consent as part of sample acceptance criteria

CAPA and Risk-Based Approaches for Harmonization

To address discrepancies and enhance inspection readiness, sponsors and CROs must implement a CAPA framework that identifies root causes of compliance gaps and enforces risk-based preventive measures. Key elements include:

1. Establishing SOPs that clearly identify the regulatory context (GLP, GCP, or both)
2. Conducting risk assessments when transitioning a process from GLP to GCP settings
3. Performing internal audits with checklists that include both sets of requirements
4. Training QA and lab personnel on overlapping compliance responsibilities

Documentation and Data Integrity in Hybrid Models

Hybrid GLP/GCP studies require meticulous attention to data integrity. Laboratory Information Management Systems (LIMS) should support 21 CFR Part 11 compliance, while audit trails must be preserved for both raw and electronic records. Additionally, sample labeling, transfer logs, and processing documentation should be accessible for inspection in formats compatible with both GLP and GCP.

The integration of informed consent data, subject codes, and sample metadata into tracking logs is particularly important in GCP-governed studies. Cross-checking logs from sample receipt to analysis is a common area of scrutiny during inspections.

Case Study: GLP-GCP Misalignment and Regulatory Impact

A Phase I trial for a novel CNS compound involved pharmacokinetic sampling at a GCP site and subsequent analysis at a GLP-accredited lab. While the lab followed GLP SOPs for sample processing, it failed to cross-verify subject data with clinical eCRFs. During inspection, FDA found no linkage between consented subjects and their processed samples—resulting in a warning letter citing failure to ensure subject-level traceability in compliance with GCP.

This example highlights the regulatory expectation that GCP principles must govern all trial-related laboratory activities when human data is involved.

Regulatory References and Guidance

• FDA’s Bioanalytical Method Validation Guidance (2018)
• ICH E6(R2): Integrated Addendum to GCP
• OECD Principles of Good Laboratory Practice
• Australia and New Zealand Clinical Trials Registry

Conclusion: Establishing Integrated Compliance Systems

As the line between preclinical and clinical bioanalytical testing continues to blur, sponsors must ensure that labs operate with a dual compliance mindset. This includes harmonized SOPs, risk-based CAPA systems, appropriate training, and documentation frameworks that satisfy both GLP and GCP expectations. Whether through internal QA programs or external audits, continuous oversight is necessary to maintain data quality and regulatory compliance in hybrid study models.